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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma is disease derived from squamous cell epithelium. It is closely 
associate with EBV infection, which its latent infection express several genes, including latent membrane 
protein-1 (LMP1). LMP1 is associate with the growth of tumor by activating several signaling pathway and 
gene expression. 
Objective: This study was conducted to analyze the overexpression of LMP1 based on T stage.  
Methods: This was a cross-sectional design with statistical analysis. We used CT scan with contrast to evaluate 
the primary tumor size based on AJCC 2010. The overexpression of LMP1 was assessed by 
immunohistochemistry staining based on IRS. The study was conducted in Adam Malik General Hospital 
Medan, Indonesia. Fisher exact test was used to analyze the association of LMP1 overexpression and T stage. 
Results: Our study showed the overexpression of LMP1 was most common in stage T3 with 23 (37.1%) 
samples. Then followed by stage T4, T2, and T1 with 20 (32.3%), 16 (25.8%), and 3 (4.8%) samples 
respectively. There was not significant association of LMP1 overexpression with T stage (p > 0.05).  
Conclusion: The overexpression of LMP1 is found mostly in late T stage including T3 and T4. Different with 
our hypothesis, there was not association of T stage with LMP1 overexpression. We suggested the LMP1 was 
in indirect role in the growth of tumor as it not strong enough to affect the T stage. However, the highest 
expression in late stage supported for LMP1 used as prognostic biomarker and may be applicative in targeted 
therapy of nasopharyngeal carcinoma. 
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Nasopharyngeal carcinoma is a disease derived from squamous cell 
epithelium. It is a unique head and neck cancer which shows clearly 
geographic distribution. It has high incidence in Southern Region of China, 
Southeast Asia, Alaska, and Greenland. Incidence of nasopharyngeal 
carcinoma was reported accounting for 86.500 cases, and about 0.6% of all 
cancers in 2012 [1, 2]. Nasopharyngeal carcinoma is known closely related 
to Epstein Barr Virus infection, although it also need the involvement of 
genetic and environment influenced in pathogenesis of the disease [3].  
EBV is a part of herpes virus which infect about 90% humans in the world 
and remain in the human body in their life. It is a double strand DNA virus which 
common found in undifferentiated type of carcinoma than keratinizing squamous 
cell carcinoma [4]. EBV infection may be lytic infection which occurs in normal 
epithelial cells or established latent infection as an early step of carcinogenesis 
[3]. Latent EBV infection is the latency of EBV in infected cells with release of 
limited viral gene expression and nothing production of the viral particles. 
However, lytic infection is characterized by the production of viral particles in 
large number and the host cell’s death that promotes by the viral protein which is 
immunogenic in majority [4]. 
EBV latent infection expressed gene responsible for the carcinogenesis of 
nasopharyngeal carcinoma including the Epstein Barr virus nuclear antigen 
(EBNA), latent membrane protein-1 (LMP1), LMP-2, EBV encoded small 
RNAs (EBER), and miRNAs derived from BamHI-A rightward transcripts 
(miR-BARTs) [5]. The most common expressed gene is LMP1 which accounting 
for 60% expressed in nasopharyngeal carcinoma tissue [6]. LMP1 act as signals 
regulation from internal membrane network. It activates canonical (p65/p50) and 
non-canonical (p105/p50) NF-κB cascades, MAPK kinase pathways (Erk1/2, 
JNK, p38), STAT3, the PI3-kinase/akt cascade, PERP/eiF2α, Wnt signaling, and 
PKC δ. The activation of the signaling pathways are contribute to development 
of nasopharyngeal carcinoma [4, 7].  
LMP1, by activating several signaling pathway and induce genes 
expression are involved in the growth of tumor [3]. It upregulates epidermal 
growth factor receptor (EGFR), which is known as the most overexpressed 
growth stimulating factor in nasopharyngeal carcinoma. EGFR is activated 
by LMP1 in NF-κB dependent manner. It increase cell proliferation by 
expression of cyclin D1, cyclin E, and E2F1 which accelerate the transition 
of G1-S phase [8]. Another role of LMP1 in the tumor growth are inhibit 
apoptosis of the cells. It acts by blocking the function of p53 which was 
thought as the result of MAPK activation lead to p53 phosphorylation. The 
overexpression of p53 in nasopharyngeal carcinoma was suggested as the 
indicator of p53 inhibition due to LMP1 expression [9].  
Expression of LMP1 was found in the EBV-related cancer including 
nasopharyngeal carcinoma, lymphoma, and even gastric cancer in just one 
case with weak expression of LMP1 [10-12]. EBV-positive lymphoma 
secretes several cytokines and chemokines that responsible in the 
malignancies development, including IFN-γ, IL-9, IL-10, and interferon-
gamma-inducible protein (IP)-10. IL-9 and IL-10 promotes cell 
proliferation, in which IL-10 also increase the expression of LMP1 and 
CD25 generating proliferation. However, the IP-10 acts in increase invasive 
potentiation of cells [12]. In gastric cancer, LMP1 expression is rare 
although the association of EBV with the clinicopathological parameter well 
established [11]. This was supported from the study by Luo et al. which not 
found any expression of LMP1 in the gastric carcinoma patients. It was 
thought that the role of LMP1 in upregulation of EFGR as the reason of this 
gene was stated for its involvement in the carcinogenesis of non-lymphoid 
cell carcinomas [13].  
According to its role in activating several signaling pathway, 
manipulation of LMP1 expression is known to be part of treatment 
strategy for nasopharyngeal carcinoma [14]. Studies revealed that 
inhibition of LMP1 expression reduce cell proliferation and increase 
tumor regression [14, 15]. We suggested the role of LMP1 in the primary 
tumor enlargement which describe in the highest occurrence of it in late 
T stage (T3 and T4) as well as the significant association of its 
overexpression with T stage. This study may provide the insight of LMP1 
as the prognostic biomarker and application of its manipulation in the 
treatment of nasopharyngeal carcinoma. 







2. MATERIALS AND METHODS 
2.1  Patients and Samples 
The total patients in our study was 70 patients. Patients were diagnosed 
with nasopharyngeal carcinoma based on history taking, physical 
examination and biopsy in Adam Malik General Hospital during 2016-2017 
period. The patients met the inclusion criteria and exclusion criteria, 
including agreement in joining the study, not suffering any other 
malignancies, and had not received any radiotherapy and chemotherapy 
treatment. The samples were the cut section of paraffin block from 
nasopharyngeal carcinoma biopsies of patients which had performed 
immunohistochemistry staining. 
LMP1 expression and T stage are established as the variables in the 
study. We used the American Joint Committee on Cancer (AJCC) staging 
system 2010 to determine the staging of the patients. CT scan with contrast 
was used to evaluate the primary tumor size based on AJCC 2010. WHO 
criteria was used to identify the histopathological type of cancer. Expression 
of LMP1 were evaluated by immunohistochemistry staining. The study has 
been approved by the Health Research Ethical Committee, Medical Faculty 
of Universitas Sumatera Utara/Adam Malik General Hospital and the 
methods did not contradicted with the Declaration of Helsinki.  
2.2  Immunohistochemistry Staining 
A total 70 paraffin blocks were cut into section. It then deparaffinazed 
with xylol and then been rehydrated. We used the Dako Epitope Retrieval to 
performed antigen retrieval of the samples and heated it at 980C for 15 
minutes. Then, the tissue were washed with phosphate-buffered saline. 3% 
hydrogen peroxide was used to block the activity of endogenous peroxidase. 
The specimens were incubated with the anti-LMP1 antibody. Two 
pathologist then evaluated the overexpression of LMP1 without prior 
knowing the clinical characteristics of the patients. Overepression of LMP1 
was based on immunoreactive score (IRS). The intensity of staining (scored 
as 0=negative, 1=weak, and 2=strong) and the percentage of stained tumor 
cells (scored as 0=no stained tumor cells, 1=1%–10% stained tumor cells, 
2=11%–50% stained tumor cells, and 3=51%–100% stained tumor cells) 
was multiplied and resulting in an immunoreactivity score (IRS) ranging 
from 0 to 5. It called positive of LMP1 overexpression if  IRS was more 
than or same as 2 [16].  
 
 
Picture 1. Expression of LMP1 in non-keratinizing squamous cell 
nasopharyngeal carcinoma (x 400) 
 
2.3  Statistical Analysis 
The data gathered from the study were analyzed using the Statistical 
Package for Social Sciences (SPSSTM) computer program. We identify the 
distribution of the patients based on age, gender, the histopathological 
type, and T stage. The association of LMP1 overexpression with T stage 
were analyzed using the Fisher exact test. The correlation is found if P 
value < 0.05. 
3. RESULTS 
Distribution of the patients based on age, gender, histopathological type 
and T stage are shown in table 1. The age group 41-60 years old were the 
most common in nasopharyngeal carcinoma patients. It accounted 41 
patients (58.6%) and then followed by the age group >60 years old with 15 
patients (21.4%). The least were the age group 21-40 years old and <20 
years old with 13 patients (18.6%) and 1 patients (1.4%) respectively. Based 
on gender, there were 51 males (72.9%) and 19 females (27.1%).  
Table 1. Distribution of the Patients 
             Characteristic   n       % 
Age (years)    
 ≤20   1 1.4 
 21–40 13 18.6 
 41–60 41 58.6 
 >60 15 21.4 
Sex    












Keratinizing Squamous Cell 
Carcinoma 
Non-Keratinizing Squamous Cell 
Carcinoma 
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Non-keratinizing squamous cell carcinoma was the most common 
histopathological type accounting for 56 (80.0%) nasopharyngeal 
carcinoma patients. The second was undifferentiated carcinoma type with 9 
patients (12.9%) and the least was keratinizing squamous cell carcinoma 
with 5 patients (7.1%). Based on T stage, stage T3 was the highest 
occurrence in nasopharyngeal carcinoma patients and were followed by T4 
and T2 with 20 (28.6%) and 19 (27.1%) NPC patients. The least was stage 
T1 with 4 (5.7%) of nasopharyngeal carcinoma patients.  
Table 2. LMP1 Expression Based on T Stage in NPC 
Characteristic 
LMP1 Expression 
Overexpression % Negative % 
T Stage     
 T1   3    4.8   1 12.5 
 T2 16 25.8   3 37.5 
 T3 23 37.1   4 50.0 
 T4 20 32.3   1   0.0 
P=0.059* 
*Fisher’s exact test 
Table 2 showed LMP1 overexpression was found in 62 samples 
(88.6%) and were not found in 8 samples (11.4%). The overexpression of 
LMP1 was most common in stage T3 with 23 (37.1%) samples. The second 
for the highest occurrence of LMP1 overexpression was stage T4 with 20 
(32.3%) samples. It then followed by stage T2 with 16 (25.8%) samples and 
the lowest occurrence of LMP1 overexpression was in stage T1 with 3 
(4.8%) samples. We found there was not significant association of LMP1 
overexpression with T stage (P>0.05).  
4. DISCUSSIONS 
Our study showed the stage T3 and T4 was the most common of T stage 
in nasopharyngeal carcinoma patients. The disease is mostly asymptomatic 
causes patients of nasopharyngeal carcinoma come to the clinicians in late 
stage [17]. Study by Li et al. showed the most T stage in nasopharyngeal 
carcinoma patients were T3 and T4 in 38 of 49 patients [18]. It also 
supported by Lourembam et al. in their study which presented T3 and T4 as 
the most common T stage in 64 of 98 patients (65.7%). Liu et al. showed the 
high occurrence of stage T nasopharyngeal carcinoma presented in stage T1-
T2  than T3-T4 with 116 of 162 (70,3%) stage T1-T2 and 48 of 162 (29.3%) 
stage T3-T4 [19]. Li et al. also showed that stage T1 and T2 was occurred 
in nasopharyngeal carcinoma patients more than stage T3 and T4 in 96 of 
142 patients [20]. The early recognition of the disease may affect the 
distribution of the T stage tumor in nasopharyngeal carcinoma patients. 
LMP1 is integral membrane protein which is oncogenic protein 
expressed by EBV latent infection. It consist of three domains including a 







short N-terminal cytoplasmic tail (amino acids 1-23), six hydrophobic 
transmembrane loops and a long C-terminal cytoplasmic region (amino 
acids 187-386). C-terminal region is responsible in LMP1 signaling 
pathway. It divides by C-terminal activation region 1, 2, and 3 (CTAR-1, 
CTAR-2, and CTAR-3). C-TAR-1 promotes cell proliferation and CTAR-2 
in outgrowth of lymphoblastoid cell lines. However, CTAR-3 is an 
additional region which located between CTAR-1 and CTAR-2 [8, 21]. 
LMP1 has wide influence in the progression of cancer due to its role in 
activate several signaling pathway and genes expression [8, 22]. It is an 
expressed gen in latent EBV infection and the promoter is induced by the 
transcription factor Epstein-Barr virus nuclear antigen 2 (EBNA2) [23, 24]. 
LMP1 promotes survival of EBV-infected cells and activate NF-κB, AP-1, 
JAK/STAT, PKC, mitogen-activated protein kinase (MAPK) pathway, and 
PI3K/Akt [8, 9]. Activation of NF-κB by LMP1 lead to the expression of 
several genes responsible for tumorigenesis of nasopharyngeal carcinoma. 
AP-1 is oncogenic which involved in cell transformation, proliferation, 
apoptosis, and differentiation. The crosstalk between AP-1 and NF-κB is 
necessary in LMP1 mediated tumorigenesis [8]. LMP1 is responsible for the 
malignancies by enhance cell growth, protect cells from apoptosis, 
angiogenesis, survival of cells, and promote motility of cells [25, 26].  
In the proliferation, LMP1 associate with EGFR for the growth of the 
tumor. It regulates the phosphorylation of EGFR as well as induce its 
expression. Mechanism of inducing is dependent of the activation of NF-κB 
signaling pathway. EGFR activation with alteration of cell cycle through the 
activation of cyclin D1, cyclin E, and E2F1 which accelerate the transition 
of G1-S phase [8]. The role of LMP1 in apoptosis is through stimulation of 
anti-apoptotic molecule including TNFAIP3/A20, Mcl-1, c-IAP2 (BIRC3) 
and survivin (BIRC5) dependent NF-κB. Study by Guo et al. showed that 
LMP1 upregulates expression of survivin and promotes it translocation to 
nucleus with p53. Accumulation of survivin and p53 in nucleus lead to 
progression of G1-S phase but not enhance the apoptosis in nasopharyngeal 
carcinoma [27]. Faqing et al. in their study also associate the relation of 
LMP1 and survivin in nasopharyngeal carcinoma. LMP1 induce survivin 
resulted in the inhibition of apoptosis. They concluded with the statement 
that the expression of surviving induced by LMP1 may increase 
proliferation and inhibit apoptosis [28]. 
We suggested the association of LMP1 in the growth of tumor. Study 
by Yang et al. showed the inhibition of cell proliferation in the treatment of 
nasopharyngeal carcinoma cells with DNAzymes. This synthetic single-
stranded DNA catalysts act in genetic manipulation of LMP1. It down-
regulate the expression of LMP1 in nasopharyngeal carcinoma. The effect 
of the treatment thus down-regulate the signaling pathway activated by 
LMP1 including NF-κB, AP-1, and JAK/STAT. Their study also revealed 
the role of DNAzymes in  blocking EGFR signaling pathway which 
responsible in the proliferation of cells [14]. Their study also supported by 
Ke et al. which showed the effect of DNAzymes in the mice suffered 
nasopharyngeal carcinoma after the inoculation of the cancer cell in its 
flank. The result was down-regulation of LMP1 in the cancer cells. It also 
showed signification of decreased mean tumor weight and volume after the 
DNAzymes intratumoral injection [29].  
Study by Lin et al. showed the effectiveness of LMP1 vaccine in 
suppressing tumor growth. The injection of LMP1 vaccine lead to 
suppression of LMP1 expressing growth tumor in vivo. It also showed that 
the vaccine had role in the prevention of LMP1 expressing tumor 
development in vivo. The previous study were suggested LMP1 vaccine as 
the adjunction therapy in nasopharyngeal carcinoma patients. Similar with 
study by Yang et al. and Ke et al which suggested genetic manipulation of 
LMP1 in the treatment of nasopharyngeal carcinoma [14, 29].   
Our study showed the overexpression of LMP1 (88.6%) more than the 
negative overexpression (11.4%). There was not association of T stage with 
LMP1 overexpression in nasopharyngeal carcinoma patients. This study 
was supported by Li et al. showed the expression of LMP1 in 24 of 56 (43%) 
nasopharyngeal carcinoma patients. However, there was not found any 
significant association of LMP1 expression with tumor value, N stage, and 
clinical stage in their study. Wang et al. in their study resulted in 38 of 61 
(62.3%) LMP1 positive cases. Their study also revealed the significant 
association of LMP1 expression with TNM stage/clinical staging but not 
analyze the association of it with primary tumor size [11].  
There was 36 of 40 (90%) patients which showed LMP-overexpression 
in study conducted by Borthakur et al. There was the association of 
histopathological type and the expression of LMP1 in their study [30]. It 
was thought that differentiation status of histopathological type associated 
with Wnt/β-catenin signaling pathway activation. This phenomenon was 
most found in the non-keratinizing squamous cell carcinoma type. This 
supported the result of our study which showed the high expression of 
LMP1 was the highest in non-keratinizing squamous cell carcinoma [31]. 
However, the association of LMP1 expression and the primary tumor size 
was not analyzed in the study by Borthakur et al. [30]. 
The study by Rosales et al. showed just 10 of 25 (40%) samples with 
positive LMP1 expression and the significant association of older age and 
parapharyngeal space invasion with LMP1 expression. They suggested 
LMP1 expression may be associate with poorer prognosis in 
nasopharyngeal carcinoma patients. They did not analyze the association of 
LMP1 overexpression with primary tumor size in nasopharyngeal 
carcinoma patients. [32]. Tabyaoui et al. in their study was not found any 
overexpression of LMP1 in nasopharyngeal carcinoma patients [33].  
Expression of LMP1 in other cancers was also revealed in several 
studies. Study by Cader et al. showed the expression of LMP1 in 28 of 49 
Hodgkin lymphoma. They associated the role of LMP1 induced anti-
apoptotic by upregulation of discodin domain receptor 1 (DDR1) initiated 
by collagen [34]. Mao et al. in their study was found the overexpression of 
LMP1 in 9 of 16 (56.25%) extranodal NK/T-cell lymphoma (ENKL) 
samples. It also showed the association of LMP1 overexpression with the 
patient prognosis. They did not showed the association of LMP1 
overexpression with Ann Arbor stage [35]. Their study also supported by 
Kanemitsu et al. which revealed the expression of LMP1 in 22 of 30 (73.3%) 
ENKL cases [36].  
In gastric cancer, Wang et al. showed there just one cases of EBV-
associated gastric cancer with positive expression of LMP1 in the weak 
LMP1 expression. Otherwise, the association of EBV infection with tumor 
differentiation, tumor location, and lymph node metastasis was significant, 
although the EBV-positive in gastric cancer patients was just 30 of 600 (5%) 
patients. They suggested the difference of EBV latent infection mechanism 
in nasopharyngeal carcinoma and EBV-associated gastric cancer [11]. Luo 
in their study showed there was not any expression of LMP1 in EBV-
associated gastric carcinomas. They suggested that LMP1 was not necessary 
for the malignancy state of that cancer, however it may involve in early stage 
of cancer [13]. Lee at al. also showed the same result in nothing expression 
of LMP1 in gastric cancer [37]. 
5. CONCLUSION 
Our study showed the overexpression of LMP1 in 62 samples (88.6%) 
of nasopharyngeal carcinoma patient more than negative one. Despite for 
theories and the some studies, there was not association of LMP1 
overexpression with T stage of NPC. However, our study also supported by 
one study with others study did not analyze the association of LMP1 and T 
stage. We suggested that involvement of LMP1 to T stage is an indirect role 
and may need others gene to strong enough affecting the primary tumor. 
Further studies in largest samples is needed to fully describe the association 
of those two. Otherwise, LMP1 as prognostic biomarker as well as target 
therapy in nasopharyngeal carcinoma may give beneficial outcome.  
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